Affinia Therapeutics

MA - WalthamBiotechnology1 H-1B visas (FY2023)

Focus: Affinia Therapeutics is a newly founded (2024) gene delivery-focused biotech headquartered in Waltham, MA, specializing in gene therapy approaches to serious diseases. The company is at a very early stage with a nascent pipeline and limited public information on scale.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Affinia Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Affinia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

INVU fetal monitoring system

Pregnancy

N/A

Clinical Trials (1)

NCT06741735Study of Fetal Health Outcomes: Working With a Missouri E-telehealth Platform (The SHOW-ME Study)

N/A

Help build intelligence for Affinia Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a 2024-founded company with gene delivery focus—potential for significant equity upside if pipeline validates
Early-stage biotech environment allows broad responsibility and direct impact on science direction before organizational bureaucracy sets in
Gene therapy is a high-conviction therapeutic area with strong venture/institutional investor interest

Watch Out For

Zero active job openings as of last data refresh—hiring may be minimal or paused despite 2024 founding
No disclosed funding amount, revenue, or cash position; extreme financial opacity creates employment stability risk
Minimal pipeline maturity: only 3 trials total, no Phase 3 programs, and only 1 Phase 1/2 program in gene therapy (AFTX-201 for DCM) with no published data or clinical milestones

Generated by Claude from Affinia Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AFTX-201

Dilated Cardiomyopathy (DCM)

Phase 1/2

Clinical Trials (1)

NCT07426419An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)

Phase 1/2

Implementation bundle for Asthma Management

Moderate to Severe Asthma

Phase 4

Implementation bundle

Moderate to Severe Asthma

Phase 4

Clinical Trials (1)

NCT07241117CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Cardiovascular, Respiratory

H-1B (2023): 1 approval

Therapeutic Area Focus

Cardiovascular

1 pipeline

Respiratory

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

May 2021

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo